Literature DB >> 33767662

Adaptive Balance in Posterior Cerebellum.

Neal H Barmack1, Vito Enrico Pettorossi2.   

Abstract

Vestibular and optokinetic space is represented in three-dimensions in vermal lobules IX-X (uvula, nodulus) and hemisphere lobule X (flocculus) of the cerebellum. Vermal lobules IX-X encodes gravity and head movement using the utricular otolith and the two vertical semicircular canals. Hemispheric lobule X encodes self-motion using optokinetic feedback about the three axes of the semicircular canals. Vestibular and visual adaptation of this circuitry is needed to maintain balance during perturbations of self-induced motion. Vestibular and optokinetic (self-motion detection) stimulation is encoded by cerebellar climbing and mossy fibers. These two afferent pathways excite the discharge of Purkinje cells directly. Climbing fibers preferentially decrease the discharge of Purkinje cells by exciting stellate cell inhibitory interneurons. We describe instances adaptive balance at a behavioral level in which prolonged vestibular or optokinetic stimulation evokes reflexive eye movements that persist when the stimulation that initially evoked them stops. Adaptation to prolonged optokinetic stimulation also can be detected at cellular and subcellular levels. The transcription and expression of a neuropeptide, corticotropin releasing factor (CRF), is influenced by optokinetically-evoked olivary discharge and may contribute to optokinetic adaptation. The transcription and expression of microRNAs in floccular Purkinje cells evoked by long-term optokinetic stimulation may provide one of the subcellular mechanisms by which the membrane insertion of the GABAA receptors is regulated. The neurosteroids, estradiol (E2) and dihydrotestosterone (DHT), influence adaptation of vestibular nuclear neurons to electrically-induced potentiation and depression. In each section of this review, we discuss how adaptive changes in the vestibular and optokinetic subsystems of lobule X, inferior olivary nuclei and vestibular nuclei may contribute to the control of balance.
Copyright © 2021 Barmack and Pettorossi.

Entities:  

Keywords:  Purkinje cell; cerebellum; corticotropin releasing factor; inferior olive; microRNA; otolith; semicircular canal; vestibular

Year:  2021        PMID: 33767662      PMCID: PMC7985352          DOI: 10.3389/fneur.2021.635259

Source DB:  PubMed          Journal:  Front Neurol        ISSN: 1664-2295            Impact factor:   4.003


  3 in total

1.  Long-Lasting Efficacy of Radio Electric Asymmetric Conveyer Neuromodulation Treatment on Functional Dysmetria, an Adaptive Motor Behavior.

Authors:  Vania Fontani; Arianna Rinaldi; Chiara Rinaldi; Laura Araldi; Alida Azzarà; Antonio M Carta; Nicoletta Casale; Alessandro Castagna; Maurizio Del Medico; Maurizio Di Stasio; Marina Facchini; Monica Greco; Savino LaMarca; Giovanni Loro; Anna Marrone; Alessandra Palattella; Giulio Pellegata; Daniele Ruini; Corrado Schmitt; Franco Vianini; Margherita Maioli; Carlo Ventura; Franco Caltabiano; Adriano J Bueno; Amélia Fugino Matuoka; Edison Massahiro Nabechima; Fabio A Bechelli; Fabricio da Silveira Bossi; Greice C Nitschke Fontana; Jaques Finkielsztejn; José Alfredo Coelho Pereira; Juarez Nunes Callegaro; Kleiner Vasconcelos Pinheiro; Lara R Ferreira Alves; Marcelo Kodja Daguer; Márcia C Marins Martins; Mauricio Bezerra Uliana; Nelson Knop Zisman; Paulo Cezar Schütz; Paulo R Fochesato; Pollyanna Celso Felipe de Castro; Rosa M Tanaka Nabechima; Roseli B Randon; Salvatore Rinaldi
Journal:  Cureus       Date:  2022-06-08

2.  Sustained Loss of Bdnf Affects Peripheral but Not Central Vestibular Targets.

Authors:  Karen L Elliott; Jennifer Kersigo; Jeong Han Lee; Ebenezer N Yamoah; Bernd Fritzsch
Journal:  Front Neurol       Date:  2021-12-16       Impact factor: 4.003

3.  Balance Adaptation While Standing on a Compliant Base Depends on the Current Sensory Condition in Healthy Young Adults.

Authors:  Stefania Sozzi; Marco Schieppati
Journal:  Front Hum Neurosci       Date:  2022-03-25       Impact factor: 3.169

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.